Edit
TransThera Sciences (Nanjing), Inc.
https://www.transthera.com/Last activity: 27.06.2025
Active
药捷安康（南京）科技股份有限公司是江北新区的一家创新型小分子新药研发公司，主要开发针对未被满足临床需求且差异化明显的创新药物。药捷安康在研新药品种覆盖肿瘤、免疫等多个疾病领域。药捷安康将针对这些疾病领域深耕不辍，持续创新，致力发展成为国际一流的生物医药公司。
Mentions in press and media 9
| Date | Title | Description |
| 27.06.2025 | TransThera Publishes Translational Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Annals of Oncology | NANJING, China and GAITHERSBURG, Md., June 27, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced that the translational studies of tinengotinib in CCA with acquired resistance to FGFR inhibitors were published... |
| 10.12.2024 | 【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies | NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discoverin... |
| 09.12.2024 | 2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC) | NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to di... |
| 12.04.2024 | 【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations | NANJING, China and GAITHURSBURG, Md., April 12, 2024 /PRNewswire/ -- TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 202... |
| 08.03.2024 | TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by Europea... | NANJING, China and GAITHURSBURG, Md., March 8, 2024 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced that the randomized, controlled, global multic... |
| 26.02.2024 | TransThera initiates IND-Enabling studies for TT-02332, a novel, highly potent and CNS-penetrating NLRP3 inhibitor | NANJING, China and GAITHURSBURG, Md., Feb. 26, 2024 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-... |
| 21.12.2023 | TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma | NANJING, China and GAITHURSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announces the first patient has been dosed in the US for... |
| 07.12.2023 | 2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer | NANJING, China, Dec. 7, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announced that an oral presentation of tinengot... |
| 09.10.2023 | TransThera announces two oral presentations of tinengotinib clinical data at 2023 ESMO and SABCS annual meetings | NANJING, China, Oct. 9, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announces to deliver two oral presentations of ... |